PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa , Pisa, Italy.\', \'Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa , Pisa, Italy.\', \'Division of Microbiology, Varese University Hospital , Varese, Italy.\', \'Pisa University Hospital , Pisa, Italy.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1080/19420862.2020.1854149
?:hasPublicationType
?:journal
  • mAbs
is ?:pmid of
?:pmid
?:pmid
  • 33319649
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.236
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33319649>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33319649>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all